A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma

Future Oncology

Volumn 7, Issue 6, 2011, Pages 715-726

  Blum, Mariela ^a   Suzuki, Akihiro ^b   Ajani, Jaffer A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

5 fluorouracil; cisplatin; gastrointestinal cancer; gimeracil; potassium oteracil; S 1; thymidylate synthase

Indexed keywords

5 FLUORO 2' DEOXYURIDINE 5' TRIPHOSPHATE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIMETABOLITE; CAPECITABINE; CISPLATIN; CYTOCHROME P450 2A6; DEOXYURIDINE PHOSPHATE; DIHYDROFOLIC ACID; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA POLYMERASE; DOCETAXEL; DRUG METABOLITE; FLUOROPYRIMIDINE; FLUOROURACIL; FLUOROURIDINE TRIPHOSPHATE; GIMERACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; TEGAFUR; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UFT; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASIA; ASIAN; ASTHENIA; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN TOXICITY; BREAST CANCER; BREAST METASTASIS; CATABOLISM; CAUCASIAN; COLON CANCER; COLORECTAL CANCER; CREATININE CLEARANCE; DEHYDRATION; DIARRHEA; DIZZINESS; DNA POLYMORPHISM; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERANCE; DRY SKIN; ELECTROLYTE DISTURBANCE; ENTERITIS; FATIGUE; FEBRILE NEUTROPENIA; FETUS DISEASE; FOOD; FOOD DRUG INTERACTION; GASTRECTOMY; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; GRANULOCYTOPENIA; HAIR LOSS; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; HYPERBILIRUBINEMIA; HYPERPIGMENTATION; HYPERTRANSAMINASEMIA; ILEUS; JAUNDICE; KIDNEY FUNCTION TEST; LEUKOPENIA; LIVER FUNCTION TEST; LIVER METABOLISM; LOW DRUG DOSE; LYMPH NODE DISSECTION; MACULOPAPULAR RASH; MALAISE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLITE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSSIFICATION; OVERALL SURVIVAL; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN SYNTHESIS; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SKELETON MALFORMATION; SKIN TOXICITY; SOLID TUMOR; STOMACH CANCER; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VERTIGO; VOMITING; YOSHIDA SARCOMA;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; OXONIC ACID; STOMACH NEOPLASMS; TEGAFUR;

EID: 79959423060     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.50     Document Type: Article

References (52)

1. Anderson WF, Camargo MC, Fraumeni JF Jr, Correa P, Rosenberg PS, Rabkin CS: Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 303, 1723-1728 (2010)
2. Prinz C, Schwendy S, Voland P: H. pylori and gastric cancer: shifting the global burden. World J. Gastroenterol. 12, 5458-5464 (2006) (Pubitemid 44501802)
3. Koizumi W, Narahara H, Hara T et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial. Lancet Oncol. 9, 215-221 (2008)
4. Van Cutsem E, Moiseyenko VM, Tjulandin S et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J. Clin. Oncol. 24, 4991-4997 (2006) (Pubitemid 46631401)
5. Wagner A.D.Unverzagt S.Grothe W.et al. Chemotherapy for advanced gastric cancer Cochrane Database Syst. Rev. 101002/14651858CD004064pub3 CD004064 2010
6. Bang Y-J, Van Cutsem E, Feyereislova A et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase III, open-label, randomised controlled trial. Lancet 376, 687-697 (2010)
7. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis group in cancer. J. Clin. Oncol. 16, 301-308 (1998)
8. Schöffski P: The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15, 85-106 (2004) (Pubitemid 38316741)
9. Lamont EB, Schilsky RL: The oral fluoropyrimidines in cancer chemotherapy. Clin. Cancer Res. 5, 2289-2296 (1999) (Pubitemid 29437304)
10. Cunningham D, Starling N, Rao S et al.: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36-46 (2008)
11. Okines AFC, Norman AR, McCloud P, Kang Y-K, Cunningham D: Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann. Oncol. 20, 1529-1534 (2009)
12. Heidelberger C, Chaudhuri NK, Danneberg P et al.: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179, 663-666 (1957)
13. Saif MW, Syrigos KN, Katirtzoglou NA: S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig. Drugs 18, 335-348 (2009)
14. DeVita VT, Lawrence TS, Rosenberg SA, Weinberg RA, DePinho RA: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. DeVita VT, Lawrence TS, Rosenberg SA, Pine JW Jr, Jacobs AE (Eds)Lippincott Williams Wilkins, PA, USA (2008)
15. Ajani J: Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107, 221-231 (2006) (Pubitemid 44043103)
16. Hiller SA, Zhuk RA, Lidak MY: Pyrimidine nucleoside analogues. N1-(a-furanidyl) derivative of natural pyrimidine bases and their antimetabolites. Dokl. Akad. Nauk SSSR 176, 332-335 (1967)
17. Shirasaka T: Development history and concept of an oral anticancer agent s-1 (TS-1®): its clinical usefulness and future vistas. J. Clin. Oncol. 39, 2-15 (2009)
18. Fujii S, Kitano S, Ikenaka K, Shirasaka T: Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann. 70, 209-214 (1979) (Pubitemid 9184704)
19. Tatsumi K, Fukushima M, Shirasaka T, Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. J. Cancer Res. 78, 748-755 (1987) (Pubitemid 17132408)
20. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 53, 4004-4009 (1993) (Pubitemid 23267702)
21. Shirasaka T, Shimamato Y, Ohshimo H et al.: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7, 548-557 (1996) (Pubitemid 26276346)
22. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 53, 4004-4009 (1993) (Pubitemid 23267702)
23. Yoshisue K, Masuda H, Matsushima E et al.: Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate) to rats. Drug Metab. Dispos. 28, 1162-1167 (2000)
24. Takechi T, Nakano K, Uchida J et al.: Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother. Pharmacol. 39, 205-211 (1997). (Pubitemid 26414256)
25. Araki H, Fukushima M, Kamiyama Y, Shirasaka T: Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo. Cancer Lett. 160, 185-191 (2000)
26. Hirata K, Horikoshi N, Aiba K et al.: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin. Cancer Res. 5, 2000-2005 (1999) (Pubitemid 29399250)
27. van Groeningen CJ, Peters GJ, Schornagel JH et al.: Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J. Clin. Oncol 18, 2772-2779 (2000) (Pubitemid 30463561)
28. Zhu AX, Clark JW, Ryan DP et al.: Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother. Pharmacol. 59, 285-293 (2007) (Pubitemid 46025515)
29. Hoff PM, Saad ED, Ajani JA et al.: Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin. Cancer Res. 9, 134-142 (2003) (Pubitemid 36109725)
30. Cohen SJ, Leichman CG, Yeslow G et al.: Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin. Cancer Res. 8, 2116-2122 (2002) (Pubitemid 34753581)
31. Chu QS, Hammond LA, Schwartz G et al.: Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin. Cancer Res. 10, 4913-4921 (2004) (Pubitemid 39099764)
32. Peters GJ, Noordhuis P, Van Groeningen CJ et al.: The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin. Cancer Res. 10, 4072-4076 (2004) (Pubitemid 38812484)
33. Taguchi T, Inuyama Y, Kanamaru R et al.: Phase I study of S-1 S-1 Study Group. Gan To Kagaku Ryoho 24, 2253-2264 (1997)
34. Ajani JA, Faust J, Ikeda K et al.: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J. Clin. Oncol. 23, 6957-6965 (2005)
35. van der Weide J, Steijns LS: Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann. Clin. Biochem. 36(Pt 6), 722-729 (1999) (Pubitemid 29520971)
36. Daigo S, Takahashi Y, Fujieda M et al.: A novel mutant allele of the CYP2A6 gene (CYP2A6. *11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 12, 299-306 (2002) (Pubitemid 34620657)
37. Chuah B, Goh BC, Lee SC et al.: Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 102(2), 478-483 (2011)
38. Chollet P, Schöffski P, Weigang-Köhler K et al.: Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)Eur. J. Cancer 39, 1264-1270 (2003) (Pubitemid 36579198)
39. Sakata Y, Ohtsu A, Horikoshi N et al.: Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-04 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer 34, 1715-1720 (1998) (Pubitemid 28474225)
40. Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58, 191-197 (2000) (Pubitemid 30189900)
41. Ajani JA, Lee FC, Singh DA et al.: Multicenter Phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 24, 663-667 (2006) (Pubitemid 46630431)
42. Boku N, Yamamoto S, Fukuda H et al.: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised Phase 3 study. Lancet Oncol. 10, 1063-1069 (2009)
43. Ajani JA, Rodriguez W, Bodoky G et al.: Multicenter Phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J. Clin. Oncol. 28, 1547-1553 (2010)
44. Ajani J, Rodriguez W, Bodoky G et al.: Multicenter Phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses. J. Clin. Oncol. 27, (Suppl. 15) Abstract 8 (2009)
45. Narahara H, Iishi H, Imamura H et al.: Randomized Phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)Gastric Cancer 14, 72-80 (2011)
46. Kubota T: The role of S-1 in the treatment of gastric cancer. Br. J. Cancer 98, 1301-1304 (2008) (Pubitemid 351543589)
47. Kim YH, Koizumi W, Lee KH, Kishimoto HC: Randomized Phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): the START trial. J. Clin. Oncol. 29, (Suppl. 4), 7 (2011)
48. Sakuramoto S, Sasako M, Yamaguchi T et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810-1820 (2007) (Pubitemid 350044801)
49. Tomiyama N, Hidaka M, Hidaka H et al.: Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer. Cancer Chemother. Pharmacol. 65, 807-809 (2010)
50. Yamanaka T, Matsumoto S, Teramukai S et al.: Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer. Gastric Cancer 10, 129-134 (2007) (Pubitemid 46955943)
51. Lee J-L, Kang YK, Kang HJ et al.: A randomised multicentre Phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br. J. Cancer 99, 584-590 (2008)
52. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br. J. Cancer 89(12), 2207-2212 (2003) (Pubitemid 38168001)